Studies with data on single-dose HPV vaccination

Study	Evidence	vaccine	Age	Results
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial [1]	Efficacy/ Immunogenicity	2 valents HPV	18–25 y	- **99.4%** 1-dose and **100.%** for 3 doses were seropositive HPV-16 - **98.8%** 1-dose and **100 %** for 3-doses, were HPV-18 seropositive.
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination [2]	Efficacy/ Immunogenicity	4 valents HPV	10–18 y	- 1 dose: **92 %** (95% CI: 87.0%–95.0%) - 2 doses: **94.8%** (95% CI: 90.0%–97.3%) - 3 doses: **95.3%** (95% CI: 90.9%–97%)
Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years [3]	Efficacy	2 valents HPV 9 valents HPV	9–14 y	- **99 %** 1-dose and **100.%** for 2 doses were HPV-16 seropositive - **98 %** 1-dose and **100 %** for 2-dose, were HPV-18 seropositive. - **100 %** 1-dose and **100.%** for 2 doses were HPV-16 seropositive - **93 %** 1-dose and **98 %** for 2-doses, were HPV-18 seropositive.

1. *JNCI Monographs*, Volume 2024, Issue 67, October-November 2024, Pages 329–336,
2. *JNCI Monographs*, Volume 2024, Issue 67, October-November 2024, Pages 317–328,
3. Lancet Glob Health . 2025 Feb;13(2):e319-e328.